Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update
TheFly reported on February 26 that Goldman Sachs increased its price target on MLTX to $11 from $10 and maintained a Sell rating.
Moonlake Immunotherapeutics (MLTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 19,751,284 | $260,321,923 | 8.76% | |
| 2. | Deep Track Capital David Kroin | 4,610,071 | $60,760,736 | 1.08% | |
| 3. | Cormorant Asset Management Bihua Chen | 4,355,433 | $57,404,607 | +119% | 2.65% |
| 4. | D E Shaw D. E. Shaw | 2,480,767 | $32,696,509 | 0.02% | |
| 5. | Logos Capital Arsani William | 1,750,000 | $23,065,000 | 1.39% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.09 | 10,870 | $98,808.30 | 627,536 | 2025-10-08 | Filing | |
| $59.90 | 58,839 | $3,524,297.23 | 8,494,151 | 2023-10-05 | Filing | |
| $57.32 | 67,814 | $3,887,017.10 | 8,435,312 | 2023-10-04 | Filing | |
| $57.25 | 150,487 | $8,615,681.72 | 8,367,498 | 2023-10-03 | Filing | |
| $57.37 | 74,911 | $4,297,644.07 | 8,217,011 | 2023-10-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.51 | 1,925 | $37,556.75 | 1,188,510 | 2026-04-10 | Filing | |
| $18.94 | 85,870 | $1,626,377.80 | 1,190,435 | 2026-04-09 | Filing | |
| $16.79 | 248,530 | $4,172,818.70 | 1,039,238 | 2026-03-31 | Filing | |
| $16.79 | 1,569,116 | $26,345,457.64 | 6,599,722 | 2026-03-31 | Filing | |
| $16.79 | 1,932,354 | $32,444,223.66 | 8,302,735 | 2026-03-31 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,267 | $42,257 | 0% | |
| 2. | 733 | $12,109 | 0% |
News See All
12 Most Promising Small-Cap Stocks According to Wall Street Analysts
Small-cap stocks are drawing renewed investor attention in 2026 as capital rotates away from years of concentration in mega-cap names.
Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play
TheFly reported on January 14 that Goldman Sachs downgraded MLTX to Sell from Neutral and set a price target of $10, up from $8.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
11 Best Stocks to Buy for the Next 3 Months According to Hedge Funds
On September 6, Rebecca Patterson, Chief Investment Strategist at Bridgewater Associates, appeared in an interview on CNBC to discuss the current US economy.
MoonLake Immunotherapeutics (MLTX): A Bull Case Theory
We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on MLTX.
Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment
MoonLake Immunotherapeutics (NASDAQ:MLTX) is a Switzerland-based clinical-stage biopharmaceutical company specializing in developing next-level medicines for immunologic diseases.
10 Stocks with Huge Catalysts on the Horizon
When the president of the US leaves a meeting with the Federal Reserve sounding confident that interest rates will fall, investors cannot help but take notice.
H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT
Selvaraju highlighted the upcoming release of top-line data from the Phase 3 VELA program for Sonelokimab as a major catalyst for the company.
11 Best Guru Stocks to Buy According to Wall Street Analysts
Wall Street seems to be breathing a little easier after the initial panic over President Trump’s tariffs earlier this month, but the rollercoaster is not over just yet.
Hedge Fund Resource Center